End-stage Renal Disease
Conditions
Interventions
Dexmedetomidine group:Intraoperative infusion of dexmedetomidine
Control group:Dexmedetomidine was not used during the operation
Sponsors
Department of Anesthesiology and Perioperative Medicine, the Second Affiliated Hospital of Anhui Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. From January 4, 2017 to August 31, 2018, patients underwent parathyroidectomy + autotransplantation in our hospital; 2. ASA II / III patients; 3. Patients who have regular hemodialysis or peritoneal dialysis three times a week.
Exclusion criteria
Exclusion criteria: 1. Patients with severe respiratory and circulatory diseases, such as severe coronary atherosclerosis, heart failure, myocardial infarction, respiratory failure and other basic diseases; 2. Patients with nervous system diseases: such as severe cerebral hemorrhage or sequelae of cerebral infarction, hemiplegia, aphasia, etc; 3. Patients with mental disorders: such as schizophrenia, depression, etc; 4. Patients with long-term drug abuse: including chemotherapy drugs, analgesics, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| hyperparathyroidism recurrenc after surgery;health-related quality of life;parathyroidectomy assessment of symptoms score;Postoperative mortality; | — |
Secondary
| Measure | Time frame |
|---|---|
| duration of anesthesia;duration of surgery;Extubation time;Intraoperative amount of sufentanil;Residence time in anesthesia recovery room;intensity of pain (numeric rate score);adverse event; | — |
Countries
China
Contacts
Public ContactWeiHan
Department of Anesthesiology and Perioperative Medicine, the Second Affiliated Hospital of Anhui Medical University
Outcome results
None listed